Voriconazole, a derivative of fluconazole, is an antifungal triazole with expanded spectrum of activity against a variety of yeasts and filamentous fungi. It exhibits fungicidal activity against Aspergillus species. Preliminary data from animal models and clinical trials show promise in the treatment of candidiasis and aspergillosis. Of concern is the development of resistance to voriconazole and cross-resistance with other azoles. Voriconazole is a welcome addition to our limited armamentarium against potentially fatal fungal infections.
No takes yet. Share an insight, caveat, or question.
Chandrasekar et al. (2001) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: